Study in Beta-thalassaemia or Myelodysplastic Syndrome Patients to Investigate the Safety and Tolerability of SLN124

NCT04176653 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Study stopped prior to subject administered first dose, due to COVID-19

Conditions

Non-transfusion-dependent Thalassemia
Low Risk Myelodysplastic Syndrome

Interventions

DRUG: SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo

Sponsor

Silence Therapeutics plc